Key clinical point: Anticipating pivotal trials due next week at ACC, investigator-led study shows excellent TAVR results in low risk patients.
Major finding: At one year, cardiovascular-related mortality was 1% and there were no disabling strokes.
Data Source: Investigator-led non-randomized study.
Disclosures: Dr. Waksman reports financial relationships with numerous manufacturers of devices for interventional cardiology including those that produce TAVR devices.
2019 Cardiovascular Research Technologies.